Premium
Omalizumab: now licensed as adjunct for urticaria
Author(s) -
Chaplin Steve,
Grattan Clive
Publication year - 2014
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1239
Subject(s) - omalizumab , medicine , adjunct , chronic urticaria , asthma , adverse effect , dermatology , immunoglobulin e , contact urticaria , intensive care medicine , immunology , allergy , pharmacology , antibody , linguistics , philosophy , contact dermatitis
Omalizumab (Xolair), which was originally licensed for IgE‐mediated asthma, is now indicated as adjunctive therapy for chronic spontaneous urticaria. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events, and Dr Clive Grattan discusses its place in therapy.